Want to see TSE:OPTI full AI Analyst Report?
OPTI Stock Chart & Stats
C$0.32
>-C$0.01(-2.38%)
At close: 4:00 PM EST
C$0.32
>-C$0.01(-2.38%)
Day’s Range― - ―
52-Week RangeC$3.15 - C$12.60
Previous CloseN/A
Volume13.36K
Average Volume (3M)169.72K
Market Cap
C$41.63M
Enterprise ValueC$26.11M
Total Cash (Recent Filing)C$106.71K
Total Debt (Recent Filing)C$6.57M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 28, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding5,625,899
10 Day Avg. Volume137,724
30 Day Avg. Volume169,715
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)5.70
Price to Sales (P/S)87.81
P/FCF Ratio-13.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth demonstrates expanding commercial traction in regulated psychedelic supply and services. Over a 2-6 month horizon, growing revenue provides a larger base to absorb fixed costs and supports scale economies, which can enable margin recovery if cost structure is managed.
GMP-capable ManufacturingGMP-compliant manufacturing is a durable competitive advantage in regulated psychedelics: it enables contract work, high-barrier supply agreements, and regulatory trust. Maintaining GMP capacity supports recurring CDMO revenue and positions the company to capture clinical and commercial demand long term.
Diversified Regulated Revenue StreamsA multi-pronged revenue model reduces single-customer dependence and leverages different demand drivers (clinical supply, third-party manufacturing, testing). This structural diversification increases resilience and offers multiple pathways to durable cash generation as the psychedelics ecosystem matures.
Bears Say
Negative Unit EconomicsNegative gross profit indicates core product/service pricing or cost issues that undermine sustainable profitability. Without improved unit economics, revenue growth alone can increase cash burn; durable recovery requires either higher margins or structural cost reductions to reach positive operating leverage.
Weak Cash GenerationPersistent negative operating and free cash flow forces reliance on external financing, constraining strategic flexibility. Over months, ongoing cash deficits can limit capital-intensive GMP operations and R&D unless financing is secured on favorable terms or cash flow turns sustainably positive.
Rising Leverage And Weaker Balance SheetMaterial increase in leverage and declining equity reduce financial resilience and increase refinancing risk. For a company with negative cash flow, higher debt levels constrain investment in capacity and R&D and raise long-term solvency concerns absent durable margin or cash-flow improvement.
Optimi Health News
OPTI FAQ
What was Optimi Health’s price range in the past 12 months?
Optimi Health lowest stock price was C$3.15 and its highest was C$12.60 in the past 12 months.
What is Optimi Health’s market cap?
Optimi Health’s market cap is C$41.63M.
When is Optimi Health’s upcoming earnings report date?
Optimi Health’s upcoming earnings report date is Aug 28, 2026 which is in 57 days.
How were Optimi Health’s earnings last quarter?
Optimi Health released its earnings results on Jun 01, 2026. The company reported -C$0.36 earnings per share for the quarter, the consensus estimate of -C$0.36 by C$0.
Is Optimi Health overvalued?
According to Wall Street analysts Optimi Health’s price is currently Overvalued.
Does Optimi Health pay dividends?
Optimi Health does not currently pay dividends.
What is Optimi Health’s EPS estimate?
Optimi Health’s EPS estimate is -0.4.
How many shares outstanding does Optimi Health have?
Optimi Health has 5,625,899 shares outstanding.
What happened to Optimi Health’s price movement after its last earnings report?
Optimi Health reported an EPS of -C$0.36 in its last earnings report, expectations of -C$0.36. Following the earnings report the stock price went up 2.532%.
Which hedge fund is a major shareholder of Optimi Health?
Currently, no hedge funds are holding shares in TSE:OPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Optimi Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth C$56.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.45%
12-Months-Change
Fundamentals
Return on Equity
-94.46%
Trailing 12-Months
Asset Growth
-1.54%
Trailing 12-Months
Company Description
Optimi Health
Optimi Health Corp. focuses on developing an integrated brand of functional mushrooms specifically for the Canadian health and wellness food markets. The company manages the entire process from the cultivation and extraction to the processing and distribution of these mushroom strains. Among the fungi varieties it offers are Lions Mane, Reishi, Turkey Tail, Chaga, and Cordyceps. Incorporated in 2020, the company was initially known as 1251418 BC Ltd. before officially changing its name to Optimi Health Corp. in August of that year. Its operations are headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
MediPharm Labs
―
PharmaCielo
―
Rubicon Organics
―
Avicanna
―
Options Prices
Currently, No data available
---